FACTORS INVOLVED IN THE DEPRESSION OF HEPATIC MIXED-FUNCTION OXIDASE DURING INFECTIONS WITH LISTERIA-MONOCYTOGENES

被引:13
作者
AZRI, S
RENTON, KW
机构
[1] Department of Pharmacology, Dalhousie University, Halifax
来源
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY | 1991年 / 13卷 / 2-3期
基金
英国医学研究理事会;
关键词
D O I
10.1016/0192-0561(91)90099-S
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A number of infections are capable of depressing the capacity of the liver to metabolize drugs. We have studied a number of factors which could be involved in the depression of cytochrome P-450 and related drug biotransformation enzymes during infections with Listeria monocytogenes. During the course of the infection, durg metabolism and heme content of hepatic microsomes were depressed but heme oxygenase was elevated. A free radical scavenger alpha-tocopherol did not prevent the loss and xanthine oxidase activities did not correlate with the time course of the loss. Infections in susceptible (balb/c) mice produced a larger loss in drug metabolism than in resistant (C57BL/6) mice, and an avirulent strain of the bacteria was without effect. A preparation of hemolysin isolated from Listeria monocytogenes produced a dose-dependent loss of cytochrome P-450 in isolated hepatocytes. These experiments indicate that the loss of drug metabolism during Listeria infections is most likely due to hemolysin released by the bacteria.
引用
收藏
页码:197 / 204
页数:8
相关论文
共 43 条
[11]  
FALK JE, 1964, PORPHYRINS METALLOPO, P181
[12]   INHIBITION OF HEPATIC DRUG-METABOLISM IN THE RAT AFTER CORYNEBACTERIUM-PARVUM TREATMENT [J].
FARQUHAR, D ;
BENVENUTO, JA ;
KUTTESCH, N ;
LOO, TL .
BIOCHEMICAL PHARMACOLOGY, 1983, 32 (07) :1275-1280
[13]   PURIFICATION, CHARACTERIZATION, AND TOXICITY OF THE SULFHYDRYL-ACTIVATED HEMOLYSIN LISTERIOLYSIN-O FROM LISTERIA-MONOCYTOGENES [J].
GEOFFROY, C ;
GAILLARD, JL ;
ALOUF, JE ;
BERCHE, P .
INFECTION AND IMMUNITY, 1987, 55 (07) :1641-1646
[14]  
GHEZZI P, 1985, CANCER RES, V45, P3444
[15]  
GHEZZI P, 1984, BIOCHEM BIOPH RES CO, V119, P144, DOI 10.1016/0006-291X(84)91630-9
[16]  
GORODISCHER R, 1976, Biochemical Pharmacology, V25, P351, DOI 10.1016/0006-2952(76)90226-4
[17]  
GROVES RD, 1977, J CLIN MICROBIOL, V5, P559
[18]  
KINGDON G C, 1970, Infection and Immunity, V1, P363
[19]  
KRAEMER MJ, 1982, PEDIATRICS, V69, P476
[20]  
LAVICKY J, 1988, TOXICON, V26, P290